ロード中...
Anti-receptor activator of nuclear factor κB ligand antibody treatment increases osteoclastogenesis-promoting IL-8 in patients with rheumatoid arthritis
The receptor activator of nuclear factor κB ligand (RANKL) is an important factor for osteoclastogenesis and contributes to the pathology of rheumatoid arthritis (RA); thus, the anti-RANKL antibody (Ab) has been expected to protect joint destruction in RA patients. IL-8 also has osteoclastogenic act...
保存先:
| 出版年: | Int Immunol |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6484893/ https://ncbi.nlm.nih.gov/pubmed/30753461 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/intimm/dxz009 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|